These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539 [TBL] [Abstract][Full Text] [Related]
5. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558 [TBL] [Abstract][Full Text] [Related]
6. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. Koe BK; Weissman A; Welch WM; Browne RG J Pharmacol Exp Ther; 1983 Sep; 226(3):686-700. PubMed ID: 6310078 [TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121 [TBL] [Abstract][Full Text] [Related]
9. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. Wong DT; Threlkeld PG; Best KL; Bymaster FP J Pharmacol Exp Ther; 1982 Jul; 222(1):61-5. PubMed ID: 6123593 [TBL] [Abstract][Full Text] [Related]
10. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870 [TBL] [Abstract][Full Text] [Related]
12. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971. Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613 [TBL] [Abstract][Full Text] [Related]
13. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. Fuller RW; Hemrick-Luecke SK; Snoddy HD J Pharmacol Exp Ther; 1994 Apr; 269(1):132-6. PubMed ID: 7513356 [TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological evaluation of the novel antidepressant and serotonin uptake inhibitor 2-(3,4-Dichlorobenzyl)-2-dimethylamino-1-propanol hydrochloride. Gouret CJ; Porsolt R; Wettstein JG; Puech A; Soulard C; Pascaud X; Junien JL Arzneimittelforschung; 1990 Jun; 40(6):633-40. PubMed ID: 2168703 [TBL] [Abstract][Full Text] [Related]
15. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995 [TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067. Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993 [TBL] [Abstract][Full Text] [Related]
17. Antinociceptive action of McN-5195 in rodents: a structurally novel (indolizine) analgesic with a nonopioid mechanism of action. Vaught JL; Carson JR; Carmosin RJ; Blum PS; Persico FJ; Hageman WE; Shank RP; Raffa RB J Pharmacol Exp Ther; 1990 Oct; 255(1):1-10. PubMed ID: 2170621 [TBL] [Abstract][Full Text] [Related]
18. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007 [TBL] [Abstract][Full Text] [Related]
19. Animal pharmacology of the selective histamine H1-receptor antagonist tazifylline. Poizot A; Dumez D; Ferrandon P; Lefournier C; Michel A; Armstrong JM Arzneimittelforschung; 1986 Apr; 36(4):695-702. PubMed ID: 2424463 [TBL] [Abstract][Full Text] [Related]
20. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]